Jared J Gartner
Overview
Explore the profile of Jared J Gartner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
5032
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Gros A, Tran E, Parkhurst M, Ilyas S, Pasetto A, Groh E, et al.
J Clin Invest
. 2019 Oct;
129(11):4992-5004.
PMID: 31609250
Tumor-resident lymphocytes can mount a response against neoantigens expressed in microsatellite-stable gastrointestinal (GI) cancers, and adoptive transfer of neoantigen-specific lymphocytes has demonstrated antitumor activity in selected patients. However, whether peripheral...
22.
Doran S, Stevanovic S, Adhikary S, Gartner J, Jia L, Kwong M, et al.
J Clin Oncol
. 2019 Aug;
37(30):2759-2768.
PMID: 31408414
Purpose: Genetically engineered T-cell therapy is an emerging treatment of hematologic cancers with potential utility in epithelial cancers. We investigated T-cell therapy for the treatment of metastatic human papillomavirus (HPV)-associated...
23.
Parkhurst M, Robbins P, Tran E, Prickett T, Gartner J, Jia L, et al.
Cancer Discov
. 2019 Jun;
9(8):1022-1035.
PMID: 31164343
Immunotherapies can mediate regression of human tumors with high mutation rates, but responses are rarely observed in patients with common epithelial cancers. This raises the question of whether patients with...
24.
Leko V, McDuffie L, Zheng Z, Gartner J, Prickett T, Apolo A, et al.
J Immunol
. 2019 May;
202(12):3458-3467.
PMID: 31036766
Immune checkpoint inhibitors are effective in treating a variety of malignancies, including metastatic bladder cancer. A generally accepted hypothesis suggests that immune checkpoint inhibitors induce tumor regressions by reactivating a...
25.
Sana G, Madigan J, Gartner J, Fourrez M, Lin J, Qutob N, et al.
J Invest Dermatol
. 2019 Mar;
139(9):1985-1992.e10.
PMID: 30905807
ABCB5 is an ABC transporter that was shown to confer low-level multidrug resistance in cancer. In this study, we show that ABCB5 was mutated in 13.75% of the 640 melanoma...
26.
Qutob N, Masuho I, Alon M, Emmanuel R, Cohen I, Di Pizio A, et al.
Sci Rep
. 2019 Mar;
9(1):4523.
PMID: 30850615
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.
27.
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Malekzadeh P, Pasetto A, Robbins P, Parkhurst M, Paria B, Jia L, et al.
J Clin Invest
. 2019 Feb;
129(3):1109-1114.
PMID: 30714987
No abstract available.
28.
Lo W, Parkhurst M, Robbins P, Tran E, Lu Y, Jia L, et al.
Cancer Immunol Res
. 2019 Feb;
7(4):534-543.
PMID: 30709841
Adoptive cell therapy (ACT) with T cells targeting neoantigens can mediate durable responses in patients with metastatic cancer. Cell therapies targeting common shared antigens for epithelial cancers are not yet...
29.
Cafri G, Yossef R, Pasetto A, Deniger D, Lu Y, Parkhurst M, et al.
Nat Commun
. 2019 Jan;
10(1):449.
PMID: 30683863
T cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor infiltrating lymphocytes, but whether such cells can...
30.
Yossef R, Tran E, Deniger D, Gros A, Pasetto A, Parkhurst M, et al.
JCI Insight
. 2018 Oct;
3(19).
PMID: 30282837
Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) targeting neoantigens can mediate tumor regression in selected patients with metastatic epithelial cancer. However, effectively identifying and harnessing neoantigen-reactive T cells for...